This review aimed to evaluate the efficacy of pharmacologic approaches to painful bladder syndrome/interstitial cystitis (PBS/IC). It concluded that pentosan polysulphate may be modestly beneficial for symptoms of PBS/IC, but there is insufficient evidence for other pharmacologic treatments. Though appropriately cautious, limitations in the reporting make it difficult to fully assess the reliability of these conclusions.
Results of the review
Twenty-one randomised controlled trials (RCTs; n=1,470) were included in the review.
The mean frequency of global improvement was 19% (range: 4 to 40) in the control groups and 49% (range: 28 to 89) in the treatment groups. Effect sizes were generally small.
For oral pentosan polysulphate, 5 RCTs gave a pooled relative risk of 1.78 (95% confidence interval: 1.34, 2.35) for patient-reported improvement in symptoms. There was no evidence of statistical heterogeneity (Q=3.53; I-squared 0%; p=0.47) or publication bias (p=0.18).
For other treatments, few studies reported data on the same outcomes for the same specific agent.
